CADONILIMAB

UNII:	6FYG1DS4NW
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	CADONILIMAB
GSRS Full Record:	6FYG1DS4NW i

2394841-59-7
AK-104
AK104
ANTI-PD1/ANTI-CTLA4 BISPECIFIC ANTIBODY AK104
CADONILIMAB [USAN]
Cadonilimab [WHO-DD]
IMMUNOGLOBULIN G1 (235-ALANINE,236-ALANINE,238-ALANINE), ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN-MUS MUSCULUS .GAMMA.1-CHAIN) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS HEAVY CHAIN V-D-J REGION) FUSION PROTEIN WITH PEPTIDE LINKER (GGGS)4 FUSION PROTEIN WITH IMMUNOGLOBULIN ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS .KAPPA.-CHAIN V-J REGION), DISULFIDE WITH HUMAN-MUS MUSCULUS .KAPPA.-CHAIN, DIMER
IMMUNOGLOBULIN G1-KAPPA ANTI-(HOMO SAPIENS PDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), EACH HEAVY CHAIN BEING FUSED TO A SCFV ANTI- (HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)), MONOCLONAL ANTIBODY, BISPECIFIC, TETRAVALENT; GAMMA1 HEAVY CHAIN ANTI-PDCD1 FUSED TO SCFV ANTI-CTLA4 (1-713) (GAMMA-1 HEAVY CHAIN(1-448) (VH ANTI- PDCD1 (HOMO SAPIENS IGHV3-23*04 (88.7%)-(IGHD)-IGHJ6*01 (90.9%) T123>L (113)) CDR IMGT (8.8.11) (26-33.51-58.97-107) (1-118)-HOMO SAPIENS IGHG1*01, G1M17,1, G1V14 CH2 A1.3, A1.2 (CH1 K120 (215) (119- 216), HINGE 1-15 (217-231), CH2 L1.3>A (235), L1.2>A (236), G1>A (238) (232-341), CH3 D12 (357), L14 (359) (342-446), CHS (447-448)) (119-448))- 20-MER TETRAKIS(TETRAGLYCYL-SERYL) LINKER (449-468)-SCFV HEAVY-LAMBDA ANTICTLA4 (469-713) (VH ANTI-CTLA4 G49>C (512) (HOMO SAPIENS IGHV1- 2*02 (84.7%)-(IGHD)-IGHJ5*01 (90.9%) S128>A (583)) CDR-IMGT (8.8.8) (494-501.519-526.565-572) (469-583)-20-MER TETRAKIS(TETRAGLYCYL-SERYL) LINKER (584-603)-V-LAMBDA ANTI-CTLA4 (HOMO SAPIENS IGLV7-46*01 (85.3%)- IGLJ3*02 (91.7%) G120>C (705)) CDR-IMGT (9.3.9) (629-637.655-657.694- 702) (604-713))); (221-214')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-PDCD1 (1'- 214') (VKAPPA (MUS MUSCULUS IGKV14-111*01 (86.3%)-IGKJ5*01 (100%)/HOMO SAPIENS IGKV1-16*01 (80.0%)-IGKJ2*01 (81.8%) Q120>A (100), I126>L (106)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); DIMER (227-227'':230-230'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, GLYCOFORM ALFA
PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR AK104
cadonilimab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

CADONILIMAB

Synonyms and Mappings

Resources